The U.S. Food and Drug Administration today approved Orbactiv (oritavancin), a new antibacterial drug to treat adults with skin infections. Orbactiv is approved to treat patients with acute bacterial skin...

The number of skin and soft tissue infections (SSTI) has skyrocketed due to the spread of methicillin resistant Staphylococcus aureus (MRSA). But many SSTIs – even those caused by the superbug MRSA –...